Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?

ConclusionsMandatory repeat HER2 testing of grade 3 HER2‐negative carcinomas is not appropriate. This is particularly true if repeat testing is performed after borderline negative amplification in the core biopsy or in HER2‐negative heterogeneous carcinomas.

Source: Histopathology - January 7, 2016 Category: Pathology Authors: Emad A Rakha, Marian Pigera, Sandra J Shin, Timothy D'Alfonso, Ian O Ellis, Andrew H S Lee Tags: Original Article Source Type: research